Greenwich Life Sciences, Inc. GLSI
We take great care to ensure that the data presented and summarized in this overview for Greenwich LifeSciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GLSI
View all-
Black Rock Inc. New York, NY309KShares$4.16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA274KShares$3.68 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA134KShares$1.8 Million0.0% of portfolio
-
Credit Agricole S A87KShares$1.17 Million0.01% of portfolio
-
Northern Trust Corp Chicago, IL74.5KShares$1 Million0.0% of portfolio
-
State Street Corp Boston, MA71.4KShares$961,8650.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny32.5KShares$437,7750.0% of portfolio
-
Garden State Investment Advisory Services LLC Red Bank, NJ17.6KShares$237,0720.07% of portfolio
-
Morgan Stanley New York, NY17KShares$229,4070.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA16.5KShares$221,6480.0% of portfolio
Latest Institutional Activity in GLSI
Top Purchases
Top Sells
About GLSI
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Insider Transactions at GLSI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2024
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
1,000
+0.38%
|
$12,000
$12.91 P/Share
|
|
Sep 26
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,500
+0.03%
|
$21,000
$14.63 P/Share
|
|
Aug 12
2024
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
800
+0.3%
|
$10,400
$13.85 P/Share
|
|
Aug 06
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+0.04%
|
$26,000
$13.81 P/Share
|
|
Aug 05
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
5,500
+0.1%
|
$71,500
$13.18 P/Share
|
|
Aug 02
2024
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
1,000
+0.38%
|
$15,000
$15.15 P/Share
|
|
Jul 23
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,500
+0.03%
|
$22,500
$15.89 P/Share
|
|
Jul 18
2024
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
1,000
+0.38%
|
$16,000
$16.0 P/Share
|
|
Jun 13
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
174,825
+3.07%
|
$2,447,550
$14.3 P/Share
|
|
Apr 01
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
3,000
+0.06%
|
$57,000
$19.08 P/Share
|
|
Mar 22
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
2,500
+0.05%
|
$47,500
$19.98 P/Share
|
|
Mar 20
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,500
+0.03%
|
$25,500
$17.68 P/Share
|
|
Mar 05
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
30,500
+0.57%
|
$366,000
$12.49 P/Share
|
|
Mar 04
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
4,100
+0.08%
|
$53,300
$13.03 P/Share
|
|
Feb 16
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
10,800
+0.2%
|
$118,800
$11.16 P/Share
|
|
Feb 15
2024
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
12,700
+0.24%
|
$139,700
$11.07 P/Share
|
|
Nov 10
2023
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.09%
|
$50,000
$10.17 P/Share
|
|
Nov 03
2023
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
3,500
+0.07%
|
$31,500
$9.11 P/Share
|
|
Oct 27
2023
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
500
+0.19%
|
$4,000
$8.57 P/Share
|
|
Oct 26
2023
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
2,500
+0.05%
|
$17,500
$7.97 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 254K shares |
|---|